'Pay to Delay' Generic Drug Case Needs Further Review, Court Says

A federal appeals court on Thursday upheld the legality of Bayer AG to pay a potential generic competitor, Barr Pharmaceuticals, to delay introduction of Cipro, a popular antibiotic. But, in an unusual move, the court said that the issue—better known as "pay to delay"—needs additional court review.

Name:
E-mail:
Website:
Please enter your comment below:

Please enter the text below: